Lillestol Research, LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$863,276	9
2024	Research	$307,353	57
2023	Research	$330,873	580
2022	Research	$376,012	654
2021	Research	$411,345	306
2020	Research	$115,268	200
2019	Research	$60,351	106

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $1,565,608 30 payments
Novo Nordisk AS $659,420 1,821 payments
Exeltis, USA Inc. $225,515 49 payments
Kowa Research Institute, Inc. $13,501 8 payments
Merck Sharp & Dohme Corporation $433 4 payments

Studies the money was for Research payments · program years 2019–2025

Ex9924-4473 $426,928 1,056 payments
A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $329,691 1 payment
Randomised Parallel Double Blind Placebo Controlled Phase 2b Study to Assess the Safety Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia SOLANO $282,336 4 payments
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $234,173 2 payments
A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi $204,216 2 payments
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event $158,226 1 payment
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $141,470 36 payments
Nn9535-4984 $125,687 615 payments
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $108,254 2 payments
Nn9924-4635 $95,132 98 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.